ORKA insider transaction filings
Oruka Therapeutics, Inc. — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen ORKA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 900 @ $109.65 · Sale (S): 300 @ $110.52 · Sale (S): 3,320 @ $112.01 · Sale (S): 2,480 @ $112.56 · +2 more | EDGAR |
| 2026-08-14 | 4 | Quinlan Paul T — General Counsel | Option exercise (M): 10,000 @ $7.80 · Option exercise (M): 42,000 @ $12.50 · Sale (S): 3,630 @ $106.05 · Sale (S): 10,434 @ $107.14 · Sale (S): 14,696 @ $107.97 · Sale (S): 10,200 @ $109.11 · +4 more | EDGAR |
| 2026-08-14 | 4 | Agarwal Arjun — Senior Vice President, Finance | Option exercise (M): 8,542 @ $12.50 · Option exercise (M): 1,458 @ $34.39 · Sale (S): 2,100 @ $104.67 · Sale (S): 2,132 @ $105.57 · Sale (S): 1,268 @ $106.63 · Sale (S): 2,142 @ $107.71 · +3 more | EDGAR |
| 2026-07-15 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 400 @ $84.36 · Sale (S): 2,497 @ $85.86 · Sale (S): 3,803 @ $86.68 · Sale (S): 300 @ $87.25 · +2 more | EDGAR |
| 2026-07-13 | 4 | Agarwal Arjun — Senior Vice President, Finance | Option exercise (M): 8,541 @ $12.50 · Option exercise (M): 1,458 @ $34.39 · Sale (S): 300 @ $83.07 · Sale (S): 3,743 @ $84.26 · Sale (S): 5,656 @ $84.90 · Sale (S): 300 @ $85.63 · +2 more | EDGAR |
| 2026-07-01 | 4 | Sandler Laura Lee — Chief Operating Officer | Option exercise (M): 5,000 @ $7.80 · Sale (S): 2,237 @ $93.85 · Sale (S): 2,263 @ $94.75 · Sale (S): 500 @ $95.47 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Fairmount Healthcare Co-Invest III L.P. — Director, 10% owner Kiselak Tomas — Director, 10% owner Harwin Peter Evan — Director, 10% owner | Conversion (C): 3,553,410 · Sale (S): 3,553,410 @ $84.43 · Conversion (C): 42,641 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Agarwal Arjun — Senior Vice President, Finance | Sale (S): 888 @ $80.01 · Sale (S): 699 @ $82.14 | EDGAR |
| 2026-06-15 | 4 | Sandler Laura Lee — Chief Operating Officer | Sale (S): 600 @ $69.69 | EDGAR |
| 2026-06-15 | 4 | Agarwal Arjun — Senior Vice President, Finance | Option exercise (M): 8,000 @ $12.50 · Option exercise (M): 1,459 @ $34.39 · Sale (S): 1,859 @ $68.34 · Sale (S): 4,340 @ $69.85 · Sale (S): 3,260 @ $70.34 · Sale (S): 395 @ $69.69 · +2 more | EDGAR |
| 2026-06-15 | 4 | Klein Lawrence Otto — Chief Executive Officer, Director | Sale (S): 1,729 @ $69.69 | EDGAR |
| 2026-06-15 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 1,636 @ $68.38 · Sale (S): 5,064 @ $69.42 · Sale (S): 300 @ $70.62 · Sale (S): 947 @ $69.69 · +2 more | EDGAR |
| 2026-06-15 | 4 | Quinlan Paul T — General Counsel | Sale (S): 733 @ $69.69 | EDGAR |
| 2026-06-12 | 4 | Dambkowski Carl — Director | Sale (S): 22,417 @ $70.13 · Sale (S): 12,583 @ $70.11 | EDGAR |
| 2026-06-03 | 4 | Martin Christopher Nathan — Director | Grant/award (A): 9,136 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Dambkowski Carl — Director | Grant/award (A): 9,136 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Kulkarni Samarth — Director | Grant/award (A): 9,136 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Fairmount Healthcare Co-Invest III L.P. — Director Harwin Peter Evan — Director, 10% owner Kiselak Tomas — Director, 10% owner | Grant/award (A): 9,136 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | BALL KRISTINE M — Director | Grant/award (A): 9,136 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Dambkowski Carl — Director | Option exercise (M): 38,689 @ $6.84 · Option exercise (M): 11,904 @ $7.80 · Option exercise (M): 11,667 @ $11.77 · Sale (S): 38,318 @ $58.43 · Sale (S): 53,447 @ $59.10 · Sale (S): 13,235 @ $59.97 · +3 more | EDGAR |
| 2026-05-18 | 4 | Agarwal Arjun — Senior Vice President, Finance | Option exercise (M): 2,000 @ $12.50 · Option exercise (M): 5,833 @ $34.39 · Sale (S): 4,190 @ $58.34 · Sale (S): 4,600 @ $59.19 · Sale (S): 800 @ $60.34 · Sale (S): 700 @ $61.16 · +2 more | EDGAR |
| 2026-05-15 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 4,800 @ $61.56 · Sale (S): 2,100 @ $62.42 · Sale (S): 100 @ $63.52 · Option exercise (M): 3,500 (derivative) @ $0 · +1 more | EDGAR |
| 2026-05-01 | 4 | Sandler Laura Lee — Chief Operating Officer | Option exercise (M): 5,000 @ $7.80 · Sale (S): 2,200 @ $62.58 · Sale (S): 1,800 @ $64.15 · Sale (S): 300 @ $65.10 · Sale (S): 400 @ $66.06 · Sale (S): 200 @ $67.16 · +2 more | EDGAR |
| 2026-04-15 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 4,227 @ $65.73 · Sale (S): 2,273 @ $66.56 · Sale (S): 500 @ $67.38 · Option exercise (M): 3,500 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-17 | 4 | Sandler Laura Lee — Chief Operating Officer | Sale (S): 600 @ $41.30 | EDGAR |
| 2026-03-17 | 4 | Agarwal Arjun — Senior Vice President, Finance | Sale (S): 395 @ $41.30 | EDGAR |
| 2026-03-17 | 4 | Klein Lawrence Otto — Chief Executive Officer, Director | Sale (S): 1,729 @ $41.30 | EDGAR |
| 2026-03-17 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 2,921 @ $40.11 · Sale (S): 2,902 @ $41.20 · Sale (S): 1,177 @ $41.94 · Sale (S): 641 @ $41.30 · +2 more | EDGAR |
| 2026-03-17 | 4 | Quinlan Paul T — General Counsel | Sale (S): 733 @ $41.30 | EDGAR |
| 2026-03-02 | 4 | Sandler Laura Lee — Chief Operating Officer | Option exercise (M): 5,000 @ $7.80 · Sale (S): 2,325 @ $33.28 · Sale (S): 2,675 @ $33.81 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 6,064 @ $32.30 · Sale (S): 936 @ $32.78 · Option exercise (M): 3,500 (derivative) @ $0 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Sandler Laura Lee — Chief Operating Officer | Grant/award (A): 32,500 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Agarwal Arjun — SVP, Finance | Grant/award (A): 17,500 @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Dambkowski Carl — Director | Other (J): 116,483 @ $0 | EDGAR |
| 2026-01-23 | 4 | Klein Lawrence Otto — Chief Executive Officer, Director | Grant/award (A): 76,700 @ $0 · Grant/award (A): 306,700 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Goncalves Joana — Chief Medical Officer | Grant/award (A): 32,500 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Quinlan Paul T — General Counsel | Grant/award (A): 32,500 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 4,381 @ $31.56 · Sale (S): 2,619 @ $32.24 · Option exercise (M): 3,500 (derivative) @ $0 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Sandler Laura Lee — Chief Operating Officer | Option exercise (M): 5,000 @ $7.80 · Sale (S): 8,748 @ $28.17 · Sale (S): 3,144 @ $29.08 · Sale (S): 1,108 @ $29.75 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Goncalves Joana — Chief Medical Officer | Option exercise (M): 3,500 @ $6.84 · Option exercise (M): 3,500 @ $7.80 · Sale (S): 641 @ $28.53 · Sale (S): 1,787 @ $29.62 · Sale (S): 1,492 @ $30.70 · Sale (S): 3,080 @ $31.58 · +2 more | EDGAR |
| 2025-12-11 | 4 | Martin Christopher Nathan — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-09-19 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Fairmount Healthcare Co-Invest III L.P. — Director, 10% owner Kiselak Tomas — Director, 10% owner Harwin Peter Evan — Director, 10% owner | Grant/award (A): 333,340 @ $15 | EDGAR |
| 2025-07-01 | 4 | Sandler Laura Lee — Chief Operating Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Dambkowski Carl — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Turtle Cameron — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Kulkarni Samarth — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Fairmount Funds Management LLC — Director, 10% owner Fairmount Healthcare Fund II L.P. — Director, 10% owner Fairmount Healthcare Co-Invest III L.P. — Director Harwin Peter Evan — Director, 10% owner Kiselak Tomas — Director, 10% owner | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | BALL KRISTINE M — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Venrock Healthcare Capital Partners III, L.P. — 10% owner VHCP Co-Investment Holdings III, LLC — 10% owner VHCP Management EG, LLC — 10% owner Venrock Healthcare Capital Partners EG, L.P. — 10% owner VHCP Management III, LLC — 10% owner Koh Bong Y — 10% owner Shah Nimish P — 10% owner | Purchase (P): 574 @ $10.90 · Purchase (P): 9,593 @ $10.95 · Purchase (P): 8,971 @ $11.86 · Purchase (P): 14,950 @ $11.63 · Purchase (P): 88,794 @ $11.44 | EDGAR |
Recent 8-K events — Oruka Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-02-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ORKA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →